Recce Pharmaceuticals Limited, known for its innovative synthetic anti-infectives, recently signed a Memorandum of Understanding (MoU) with PT Etana Biotechnologies (Etana), a leading biomedical organization in Indonesia. This collaboration aims to speed up the clinical development of Recce’s anti-infective products across Indonesia, with a focus on addressing the critical global health challenge of antimicrobial resistance (AMR).
The partnership’s primary goals involve working alongside the nationally chosen biotech sponsor, Etana, to expedite Recce’s clinical program while ensuring speed, accessibility, cost-effectiveness (including substantial Government support), and maintaining high-quality standards. By facilitating cooperation between the Australian and Indonesian governments and industry experts, this collaboration aims to enable Recce to enter and establish a presence in new markets, thus supporting its international expansion efforts.
There is a notable demand for novel therapeutics in Indonesia as the government intensifies efforts to tackle infectious diseases and antimicrobial resistance (AMR). Particularly, over 10% of Indonesia’s adult population (equivalent to 19.5 million individuals) suffer from diabetes, a condition associated with increased risks of foot, urinary tract, and surgical site infections. Additionally, recent research indicates that 15% of sepsis patients in Indonesian hospitals also have diabetes. Indonesia ranks 127th globally in terms of the age-standardized mortality rate per 100,000 population attributed to antimicrobial resistance (AMR) among 204 countries.
(Sources: BioSpectrum; Institute for Health Metrics and Evaluation)
